Will Chou

Dr. Chou brings over 15 years of healthcare experience to Aruvant, and most recently served as Vice President and Global Disease Lead for Novartis’ Cell and Gene Therapy unit, where he led the global commercial launch of Kymriah, the first CAR-T cell therapy. Prior to that role, he led the Kymriah Lymphoma clinical development program to approvals in the North America, Europe and Asia. Prior to joining Novartis, Dr. Chou worked at the Boston Consulting Group where he focused on commercial and clinical pharmaceutical strategy. Dr. Chou holds an M.B.A. from the Yale School of Management, an M.D. from the University of Pittsburgh School of Medicine, and an A.B. in politics and economics from Princeton University. Dr. Chou completed his residency in internal medicine at Yale New Haven Hospital and a fellowship in geriatrics at Yale University.